CoChat

The Impact of Inherited Retinal Diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a Cost-of-Illness Perspective

Open access
Galvin, Orla, Chi, Gloria, Brady, Laura, Hippert, Claire, Del Valle Rubido, Marta, Daly, Avril, Michaelides, Michel · 2020 · Clinical Ophthalmology

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

To date, there has been a global lack of data regarding the prevalence of conditions falling under the Inherited Retinal Diseases (IRD) classification, the impact on the individuals and families affected, and the cost burden to economies. The absence of an international patient registry, and equitable access to genetic testing, compounds this matter. The resulting incomplete knowledge of the impact of IRDs hinders the development and commissioning of clinical services, provision of treatments, and planning and implementation of clinical trials. Thus, there is a need for stronger evidence to support value for money to regulatory bodies for treatments approved, and progressing through clinical trials. To ensure a strategic approach to future research and service provision, it is necessary to learn more about the IRD landscape. This review highlights two recent cost-of-illness reports on the socio-economic impact of 10 IRDs in the Republic of Ireland (ROI) and the United Kingdom (UK), which demonstrate the comprehensive impact of IRDs on individuals affected, their families, friends and society. Total costs attributable to IRDs in the ROI were estimated to be £42.6 million in 2019, comprising economic (£28.8 million) and wellbeing costs (£13.8 million). Wellbeing costs were estimated using the World Health Organization (WHO) burden of disease methodology, a non-financial approach, where pain, suffering and premature mortality are measured in terms of disability-adjusted-life-years (DALYs). In the UK, wellbeing costs attributable to IRDs were £196.1 million, and economic costs were £327.2 million amounting to £523.3 million total costs in 2019. Accounting for over one-third of total costs, the wellbeing burden of persons affected by IRDs should be emphasized and factored into reimbursement processes for therapies and care pathways. This targeted review presents the most current and relevant data on IRD prevalence in the ROI and the UK, and the impacts (financial and non-financial) of IRDs in terms of diagnosis, wellbeing, employment, formal and informal care, health system costs, deadweight losses and issues surrounding payers and reimbursement. This review demonstrates IRD patients and their families have common issues including, the need for timely equitable access to genetic testing and counselling, equality in accessing employment, and a revision of the assessment process for reimbursement of therapies currently focused on the cost-of-illness to the healthcare system. This review reveals that IRD patients do not frequently engage the healthcare system and as such suggests a cost-of-illness model from a societal perspective may be a better format.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/opth.s241928

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Payers in the Republic of Ireland. (B) Payers in the United Kingdom.
Figure 1 (A) Payers in the Republic of Ireland. (B) Payers in the United Kingdom.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 6

  1. Sergouniotis, 2019, Ophthalmologica, 5, 1
  2. Stuart, 2018, Eye Net Mag, 2018, 43
  3. Zhao, 2019, J Ophthalmol, 21, 8524607
  4. 2014, Registries for Evaluating Patient Outcomes: A User’s Guide. Patient Registries
  5. Zhang, 2019, Mol Genet Genomic Med, 7, e916, 10.1002/mgg3.v7.9 · DOI
  6. 2017, Juggling Care and Daily Life: The Balancing Act of the Rare Disease Community

Cited by

Metadata

Authors
Galvin, O., Chi, G., Brady, L., Hippert, C., Del Valle Rubido, M., Daly, A., & Michaelides, M.
Affiliations
  • Roche (United States) (US)
  • Fighting Blindness (IE)
  • F. Hoffmann-La Roche AG (CH)
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
Corresponding author
Galvin, Orla
Venue
Clinical Ophthalmology
Published
2020-03
Volume
Volume 14
Pages
707-719
ISSN
  • 1177-5467 (ISSN-L)
  • 1177-5483
OpenAlex
W3009621895
Cited by
116
References
32
Citations by year
2026: 9 · 2025: 27 · 2024: 20 · 2023: 17 · 2022: 24 · 2021: 16 · 2020: 3
FWCI
1.44
Type
journal article
Language
en
Open access
Locations
  • Clinical ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Retina UK
  • ProQR Therapeutics
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
inherited retinal disease, economic burden, disability-adjusted life years, prevalence, access to genetic testing, genetic counseling, employment discrimination, informal care, health system costs, deadweight loss, value for money, patient and family impact, Ireland, United Kingdom, health policy planning, clinical trial access, patient registry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.